The Journal of Immunology, Vol 144, Issue 12 4648-4650, Copyright © 1990 by American Association of Immunologists

ARTICLES

Specific prolongation of MHC class II disparate skin allografts by in vivo administration of anti-IFN-gamma monoclonal antibody

AS Rosenberg, DS Finbloom, TG Maniero, PH Van der Meide and A Singer
Division of Cytokine Biology, Food and Drug Administration, Bethesda, MD 20892.

In vivo rejection of MHC class II disparate skin allografts has been thought to involve IFN-gamma-induced expression of MHC class II alloantigens because less than 3% of skin epidermal cells express MHC class II alloantigens constitutively. In our study we directly tested this hypothesis by examining the effect of in vivo administered anti- IFN-gamma mAb on rejection of MHC class II disparate skin allografts, and comparing its effect on rejection of MHC class I disparate skin allografts placed on the same individual mice. We found that anti-IFN- gamma mAb blocked the rejection of MHC class II disparate skin allografts, but had no effect on the rejection of MHC class I disparate skin allografts. These results demonstrate that endogenously produced IFN-gamma is critical for rejection of MHC class II disparate skin allografts, but not for rejection of MHC class I disparate skin allografts. Thus, this study strongly supports the concept that MHC class II rejection responses require IFN-gamma induced MHC class II expression on keratinocytes of the allograft.

This article has been cited by other articles:

				M. Surquin, A. Le Moine, V. Flamand, N. Nagy, K. Rombaut, F.-X. Demoor, P. Stordeur, I. Salmon, J.-C. Guery, M. Goldman, et al. Skin Graft Rejection Elicited by {beta}2-Microglobulin as a Minor Transplantation Antigen Involves Multiple Effector Pathways: Role of Fas-Fas Ligand Interactions and Th2-Dependent Graft Eosinophil Infiltrates J. Immunol., July 1, 2002; 169(1): 500 - 506. [Abstract] [Full Text] [PDF]

				A. C. Wiseman, B. A. Pietra, B. P. Kelly, G. R. Rayat, M. Rizeq, and R. G. Gill Donor IFN-{gamma} Receptors Are Critical for Acute CD4+ T Cell-Mediated Cardiac Allograft Rejection J. Immunol., November 1, 2001; 167(9): 5457 - 5463. [Abstract] [Full Text] [PDF]

				C. Nakajima, Y. Uekusa, M. Iwasaki, N. Yamaguchi, T. Mukai, P. Gao, M. Tomura, S. Ono, T. Tsujimura, H. Fujiwara, et al. A Role of Interferon-{{gamma}} (IFN-{{gamma}}) in Tumor Immunity: T Cells with the Capacity to Reject Tumor Cells Are Generated But Fail to Migrate to Tumor Sitesin IFN-{{gamma}}-deficient Mice Cancer Res., April 1, 2001; 61(8): 3399 - 3405. [Abstract] [Full Text]

				A. S. Diamond and R. G. Gill An Essential Contribution by IFN-{gamma} to CD8+ T Cell-Mediated Rejection of Pancreatic Islet Allografts J. Immunol., July 1, 2000; 165(1): 247 - 255. [Abstract] [Full Text] [PDF]

				S. Koga, M. B. Auerbach, T. M. Engeman, A. C. Novick, H. Toma, and R. L. Fairchild T Cell Infiltration into Class II MHC-Disparate Allografts and Acute Rejection Is Dependent on the IFN-{gamma}-Induced Chemokine Mig J. Immunol., November 1, 1999; 163(9): 4878 - 4885. [Abstract] [Full Text] [PDF]

				A. Le Moine, M. Surquin, F. X. Demoor, J. C. Noel, M.-A. Nahori, M. Pretolani, V. Flamand, M. Y. Braun, M. Goldman, and D. Abramowicz IL-5 Mediates Eosinophilic Rejection of MHC Class II-Disparate Skin Allografts in Mice J. Immunol., October 1, 1999; 163(7): 3778 - 3784. [Abstract] [Full Text] [PDF]

				B. T. Konieczny, Z. Dai, E. T. Elwood, S. Saleem, P. S. Linsley, F. K. Baddoura, C. P. Larsen, T. C. Pearson, and F. G. Lakkis IFN-{gamma} Is Critical for Long-Term Allograft Survival Induced by Blocking the CD28 and CD40 Ligand T Cell Costimulation Pathways J. Immunol., March 1, 1998; 160(5): 2059 - 2064. [Abstract] [Full Text] [PDF]